Search

Displaying results 2421 - 2430 of 4590 in total
  1. Drug

    Apraclonidine

    go.drugbank.com/drugs/DB00964
    ApprovedInvestigational

    Apraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist.

  2. Drug

    p-Fluorofentanyl

    go.drugbank.com/drugs/DB09177
    ExperimentalIllicit

    control entire families of drugs based on their structural similarity rather than scheduling each drug individually as they appeared. p-Fluorofentanyl is made with the same synthetic route as fentanyl, but … by substituting para-fluoroaniline for aniline in the synthesis.

  3. Drug

    Ramucirumab

    go.drugbank.com/drugs/DB05578
    ApprovedInvestigational

    By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation,

  4. Drug

    Flupirtine

    go.drugbank.com/drugs/DB06623
    Investigational

    It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.

  5. Drug

    Pirtobrutinib

    go.drugbank.com/drugs/DB17472
    ApprovedInvestigational

    Its high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of atrial fibrillation.

  6. Drug

    Tafamidis

    go.drugbank.com/drugs/DB11644
    ApprovedInvestigational

    Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX.[A189717] Tafamidis is structurally similar to diflusinal.

  7. Drug

    Lanolin alcohols

    go.drugbank.com/drugs/DB14181
    Approved

    Lanolin alcohols are a complex combination of organic alcohols obtained by the hydrolysis of lanolin.

  8. Drug

    Tedisamil

    go.drugbank.com/drugs/DB06200
    Experimental

    It is currently being developed by Solvay and is currently under regulatory review by the United States Food and Drug Administration.

  9. Drug

    Olmesartan

    go.drugbank.com/drugs/DB00275
    ApprovedInvestigational

    [A175330] It was developed by Daiichi Sankyo Pharmaceuticals and approved in 2002.[A175345, L12882] … ARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling.

  10. Drug

    SPC2968

    go.drugbank.com/drugs/DB06351
    Investigational

    SPC2968 is a synthetic antisense oligodeoxynucleotide targeting hypoxia-inducible factor-1alpha (HIF-1alpha). It was under investigation in clinical trial NCT02564614 (A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic ...